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Abstract
Introduction Estrogen receptor (ER)-positive breast cancers
are considered prognostically more favorable than ER-negative
tumors, whereas human epidermal growth factor receptor
(HER)2/neu-positive breast cancers are associated with worse
prognosis. The objective of the present study was to determine
whether ER-positive and ER-negative status relates to
epigenetic changes in breast cancer-related genes. To evaluate
epigenetic differences in tumor-related genes relating to ER and
HER2/neu status of primary tumors, we examined the promoter
methylation status of the promoter region CpG islands of eight
major breast tumor-related genes (RASSF1A,  CCND2,
GSPT1, TWIST, APC, NES1, RARβ2, and CDH1).
Methods Paired ER-positive (n = 65) and ER-negative (n = 65)
primary breast tumors (n = 130) matched for prognostic factors
were assessed. DNA was extracted from paraffin-embedded
tumor tissue after microdissection, and methylation-specific
PCR and capillary-array electrophoresis analysis were
performed.
Results In early stages of tumor progression (T1 and N0),
RASSF1A  and  CCND2  were significantly (P  < 0.05) more
methylated in ER-positive than in ER-negative tumors. GSTP1
hypermethylation was more frequent in the lymph node
metastasis positive group than in the negative group. Double
negative (ER-negative, HER2/neu-negative) breast cancers had
significantly lesser frequencies of RASSF1A, GSTP1, and APC
methylation (P  < 0.0001, P  < 0.0001, and P  = 0.0035,
respectively). Both ER and HER2/neu status correlated
independently with these epigenetic alterations.
Conclusion We demonstrated significant differences in tumor-
related gene methylation patterns relevant to ER and HER2/neu
status of breast tumors. This may be of significance in the
assessment of targeted therapy resistance related to ER and
HER2/neu status in breast cancer patients.
Introduction
Hypermethylation is an epigenetic change that blocks the pro-
moter region of a gene and results in gene silencing. In breast
cancer, tumor-related genes may be silenced by hypermethyl-
ation; many hypermethylated genes have been reported, and
silencing of these genes plays important roles in carcinogene-
sis and tumor progression [1-3]. Identification of epigenetic
changes and their correlation with other clinical factors could
lead to improvements in cancer diagnosis and treatment.
In patients with breast cancer, estrogen receptor (ER) status
is an important treatment and prognostic factor. Breast cancer
patients with ER-positive tumors generally have a more favora-
ble prognosis than do those who have ER-negative tumors.
These breast cancer patients can be treated successfully with
APC, adenomatous polyposis coli; CCND2, cyclin D2; CDH1, E-cadherin; ER, estrogen receptor; GSTP1, glutathione S-transferase P1; HER2/neu, 
human epidermal growth factor receptor 2; LN, lymph node; MSP, methylation-specific PCR; NES1, normal epithelial cell-specific 1 or kallikrein 10; 
RARβ2, retinoic acid receptor- β2; RASSF1A, RAS association domain family 1A; SLN, sentinel lymph node; TWIST, human basic helix-loop-helix 
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hormonal therapies such as tamoxifen and aromatase inhibi-
tors [4-9]. Epidemiological studies revealed that patients with
ER-positive tumors have risk profiles different from patients
with ER-negative tumors. Parity and timing of births were
inversely associated with ER-positive tumors, but not with ER-
negative tumors, and body mass index after menopause was
more strongly associated with ER-positive than with ER-nega-
tive tumors [10]. In addition, rates of ER-positive breast cancer
incidence have been shown to increase after age 50 to 54
years, whereas the rates of ER-negative breast cancer inci-
dence do not [11].
Similarly, differences in the gene expression patterns of ER-
positive and ER-negative tumors have been documented in
microarray expression studies, which identified profile differ-
ences in breast tumor subtypes [12,13]. These findings sug-
gest that ER status of breast cancer represents distinct
phenotypes. However, few studies have determined epige-
netic changes in tumor-related genes in relation to ER status
in matched-paired breast cancers.
To investigate the epigenetic differences between ER-positive
and ER-negative breast cancer, we assessed the methylation
frequency of several breast tumor-related genes that are
known to undergo hypermethylated changes in breast cancer,
and that play important roles in tumorigenesis and cancer pro-
gression. The objective of the study was to determine the
association between ER status and epigenetic changes in
these tumor-related genes.
The genes assessed were as follows: RASSF1A (RAS asso-
ciation domain family 1A; location: 3p21.3; GenBank:
AF132675), CCND2 (cyclin D2; location: 12p13; GenBank:
AF518005), GSTP1 (glutathione S-transferase P1; location:
11q13; GenBank: U12472), TWIST (human basic helix-loop-
helix DNA binding protein; location: 7p21.2; GenBank:
U80998), APC (adenomatous polyposis coli; location: 5q21-
q22; GenBank: M74088), NES1 (normal epithelial cell-spe-
cific 1 or kallikrein 10; location: 19q13.3-q13.4; GenBank:
AF024605),  RARβ2  (retinoic acid receptor-β2; location:
3p24; GenBank: X07282), and CDH1 (E-cadherin; GenBank:
L08599). RASSF1A is a putative tumor-suppressor gene that
is frequently inactivated epigenetically rather than in a muta-
tional event [14]. A direct correlation between promoter region
methylation and loss of expression has been shown in many
tumor cell lines, including breast cancer [15-18]. RASSF1A
can exert a tumor-suppressing effect by blocking oncogene-
mediated c-Jun amino-terminal kinase activation [19]. It also
associates with microtubules and contributes to the mainte-
nance of genomic stability [20]. Loss of CCND2 expression
caused by methylation is an early event in breast cancer tum-
origenesis [21]. Methylation of CCND2 has been correlated
with poor prognosis, implying that CCND2 has a tumor-sup-
pressor function [22]. GSTP1 is one of a family of enzymes
that detoxifies hydrophobic electrophiles, and may be part of a
protection system from environmental or dietary carcinogens
[23]. Our group has previously found that GSTP1 methylation
correlates with increased tumor size and increased likelihood
of sentinel lymph node metastases [24]. TWIST induces E-
cadherin mediated cell-cell adhesion and induction of cell
motility. Increased expression of TWIST correlates with tumor
invasion and metastasis [25,26]. APC gene germline muta-
tions have been shown to be associated with familial adenom-
atous polyposis. Hypermethylation of the APC  promoter is
also associated with breast cancer, especially lobular breast
cancer [27-29]. NES1 is a putative tumor suppressor gene
found to be downregulated in breast cancer [30,31]. RARβ2
is postulated to be a tumor suppressor gene. RARβ2 methyl-
ation correlates with breast cancer metastasis [32]. It is
through retinoic acid receptors that retinoids can prevent pri-
mary tumor progression [33]. CDH1 expression reduction is
regarded as one of the main molecular events involved in dys-
function of the cell-cell adhesion system, triggering cancer
invasion and metastasis. Mahler-Araujo and coworkers [34]
reported a correlation between negative or reduced CDH1
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breast cancer patients.
This study was conducted to investigate epigenetic differ-
ences in specific tumor-related genes between ER-positive
and ER-negative breast cancers. We hypothesized that ER-
positive breast tumors have different epigenetic profiles of
tumor-related genes during early stages of cancer progres-
sion. We examined the methylation status of eight genes sus-
pected of being involved in regulation of breast cancer, and
investigated the methylation status of those genes at different
stages of tumor development. We compared the methylation
status of these genes between ER-positive and ER-negative
breast tumors in early and advanced stages to investigate
whether epigenetic changes occur in early stages of primary
tumor progression.
Human epidermal growth factor receptor (HER)2/neu is an
important factor for treatment and prognosis. HER2/neu over-
expression occurs in 15% to 25% of breast tumors and is
associated with poor prognosis and resistance to hormonal
therapy [35-37]. HER2/neu and ER expression have been
reported to exhibit an inverse correlation [9,38,39]. Further-
more, previous reports have demonstrated the effect of estro-
gen on downregulation of HER2/neu production [40]. We
investigated the epigenetic differences between HER2/neu-
positive and HER2/neu-negative breast tumors relative to ER
status and further identified the epigenetic characteristics of
ER-negative, HER2/neu-negative (double-negative) breast
tumors.
Materials and methods
Tumor and patient selection
Sixty-five paraffin-embedded, invasive ER-negative and ER-
positive breast tumor pairs were matched for patient age,Available online http://breast-cancer-research.com/content/10/3/R46
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tumor size (T stage), nodal status (lymph node [LN] metastasis
positive or negative), and presence or absence of distant
metastases (M status). The primary tumor characteristics are
listed in Tables 1 and 2. HER2/neu status was originally
scored 0 to 3+, and 0 and 1+ tumors were regarded as
HER2/neu negative. Tumors were graded and staged accord-
ing to the American Joint Committee on Cancer 6th Edition
Guidelines [41]. Informed consent for use of all human speci-
mens in this study was obtained under a protocol approved by
Saint John's Health Center (Santa Monica, CA, USA)/John
Wayne Cancer Institute institutional review board.
DNA processing and methylation-specific PCR
DNA was extracted as previously described [24]. Briefly, par-
affin-embedded primary tumor specimen blocks were sec-
tioned at 10 μm and deparaffinized in 100% xylene, followed
by a 100% ethanol incubation, and stained with hematoxylin
and eosin. Tumor tissue was microdissected in comparison
with a similarly stained and cover-slipped reference slide cut
from each tissue block. DNA preparation buffer containing 50
mmol/l Tris, 1 mmol/l EDTA, 2.5% Tween-20, and Proteinase
K (QIAGEN, Valencia, CA, USA) was added to microdis-
sected tissue and incubated at 50°C overnight. DNA was
extracted from the aqueous layer using phenol-chloroform-iso-
amyl alcohol (25:24:1; Fisher Scientific, Pittsburgh, PA, USA)
and precipitated using pellet paint NF co-precipitant (Nova-
gen, Madison, WI, USA). DNA was resuspended in molecular
biology grade H2O (Fisher Scientific). DNA quantification was
performed on all specimens using the PicoGreen quantifica-
tion assay (Molecular Probes, Eugene, OR, USA). Bisulfite
modification was performed as previously described [15,24].
A panel of eight genes was assessed for methylation status:
RASSF1A, APC, TWIST, CDH1, GSTP1, NES1, CCND2,
and RARβ2. Methylation-specific PCR (MSP) was performed
using AmpliTaq Gold DNA polymerase (Perkin Elmer, Nor-
walk, CT, USA) and 50 pmol each of forward and reverse prim-
ers for methylated (M) and unmethylated (U) sequences.
Primer sequences for MSP of the eight genes are shown in
Table 3.
PCR was carried out after optimizing annealing temperatures
for each primer set to include 40 timed cycles of denaturation
at 94°C for 30 seconds, annealing for 30 seconds, and exten-
sion at 72°C for 30 seconds. Post-MSP product analysis was
performed using capillary array electrophoresis (CEQ
8000XL, Beckman Coulter, Fullerton, CA, USA), as described
previously [15,24].
Statistical analysis
Descriptive statistics were used to summarize patient charac-
teristics and gene hypermethylation status. χ2 test and Fisher's
exact test were used to compare methylation status between
ER-positive and ER-negative subgroups, and to compare
those differences according to clinical factors, such as tumor
size (T stage) and nodal status (N stage). All statistical
analyses were carried out using the SAS system (SAS, Cary,
NC, USA), and P  < 0.05 was considered statistically
significant.
Results
Methylation status of genes in ER-negative and ER-
positive tumors
Initially, the difference in methylation status of eight genes
between the age-matched and tumor background-matched
ER-negative and ER-positive groups was analyzed using χ2
tests. A representative example of methylated and unmethyl-
ated gene analysis from paraffin-embedded tissue is shown in
Figure 1. For RASSF1A, CCND2, GSTP1, TWIST, and APC
genes, the proportion of methylated genes was significantly
higher in the ER-positive than in the ER-negative tumor group.
However, no significant differences in methylation status were
detected in NES1,  RARβ2, and CDH1. Among the eight
biomarkers studied, none exhibited predominance of methyla-
tion status in ER-negative tumors by univariate analysis (Table
Table 1
Patient and tumor characteristics
Clinical factors ER negative (n = 65) ER positive (n = 65)
Menopausal status
Premenopause 35 35
Postmenopause 30 30
T stage
T1c 24 24
T2 37 37
T3 4 4
N stage
N0 38 38
N1 26 27
N2 1 0
M stage
M0 65 65
M1 0 0
AJCC stage
I1 7 1 7
IIa 28 28
IIb 16 16
IIIa 4 4
IV 0 0
HER2/neu 14/51 (27%) 15/56 (27%)
Total 65 65
ER, estrogen receptor; HER, human epidermal growth factor 
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4). Based on this finding, we conducted further analysis of the
methylation status of RASSF1A, CCND2, GSTP1, TWIST,
and APC. Second, we analyzed the differences in the methyl-
ation status of these five tumor-related genes between pre-
menopausal and postmenopausal, T1 and T2/T3, and LN
metastasis negative (N0) and positive (N1/N2) subgroups
using univariate analysis. Among these five genes, there were
no significant differences in methylation frequency between
premenopausal and postmenopausal subgroups and T1 and
T2/T3 subgroups. Only GSTP1 exhibited significantly more
frequent methylation in the N1/N2 subgroup than in the N0
subgroup (Tables 5 to 7).
Methylation status of genes in ER-negative and ER-
positive early-stage tumors
To study further the changes in tumor-related gene methyla-
tion status of both ER-positive and ER-negative breast
cancers during tumor progression, we investigated the differ-
ence between both ER-positive and ER-negative primary
tumors based on American Joint Committee on Cancer T and
N stages. First, we compared the methylation status of five dif-
ferent genes in ER-negative and ER-positive tumors for T1c
and T2/T3 stages (Table 8). The ER-positive group exhibited
more frequent methylation of RASSF1A and CCND2 in both
T1c and T2/T3 stages. GSTP1 and TWIST were more meth-
ylated in the ER-positive group in the T1c stage, but the differ-
ences did not achieve statistical significance. However, they
showed significant differences in T2/T3 stage. We examined
changes in the methylation frequency ratio (methylation fre-
quency of gene in the ER-positive group/methylation fre-
quency of gene in the ER-negative group) for each tumor-
related gene during tumor progression. No difference in the
methylation frequency ratio was observed between T1c and
T2/T3 stages for all tumor-related genes assessed.
Next, we investigated the difference in methylation of tumor-
related genes between the ER-negative and ER-positive sub-
groups of N0 and N1/N2 tumors (Table 9). The ER-positive
group exhibited significantly (P < 0.05) more frequent methyl-
ation of RASSF1A, CCND2, and GSTP1 in both N0 and N1/
N2 stages. TWIST and APC were more frequently methylated
in the ER-positive group in the N0 stage, but not significantly.
Similar to subgroups divided by T stage, there were no
differences in methylation frequency ratio for all genes
assessed between the N0 and N1/N2 subgroups.
Methylation status of tumor-related genes relevant to 
HER2/neu status
In addition to ER, we investigated differences in methylation
status of the eight genes between the HER2/neu-negative and
HER2/neu-positive tumor groups. First, we analyzed the rela-
tion between ER status and HER2/neu status. Using matched
samples, no difference was found in the frequency of HER2/
neu-positive tumors between the ER-negative and ER-positive
groups. Then, the differences in methylation status of all eight
genes were analyzed between the HER2/neu-positive and
HER2/neu-negative tumor groups. The proportion of methyl-
ated RASSF1A, GSTP1, and APC genes was significantly
greater in the HER2/neu-positive than in the HER2/neu-nega-
tive tumor group; no significant differences in methylation sta-
tus were detected for TWIST, NES1, RARβ2, and CCND2.
Among the eight biomarkers studied, CDH1 showed predom-
inance of methylation status in HER2/neu-negative tumors by
univariate analysis (Table 10). Next, we compared the methyl-
ation status of double-negative tumors versus breast cancers
expressing either ER or HER2/neu. The double-negative
breast cancer group showed less frequent methylation of
APC, GSTP1, RASSF1A, and TWIST  (Table 11). Logistic
regression analysis revealed that both ER and HER2/neu sta-
tus affect the methylation status of APC,  GSTP1, and
RASSF1A independently.
Relation between the tumor-related genes with respect 
to methylation status
The relation between the genes with respect to methylation
status is shown in Table 12. GSTP1 methylation frequency is
significantly related to methylation frequency of other genes.
RASSF1A and TWIST methylation frequencies were signifi-
cantly related to methylation frequency of three of four other
genes. CCND2 and APC methylation frequency related with
Table 2
Clinical factors by HER2/neu status
Clinical factors HER2/neu negative HER2/neu positive P valuea
T stage
T1 29 10
T2/3 49 16 NS
N stage
N0 50 15
N1 28 14 NS
Age (years) 50.2 ± 11.3 50.8 ± 12.6 NS
aχ2 test and Student's t-test. HER, human epidermal growth factor receptor; NS, not significant.Available online http://breast-cancer-research.com/content/10/3/R46
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two of four other genes. In total, we examined 10 different rela-
tionships among five genes; seven of the 10 correlations
(70%) were statistically significant (P < 0.05).
Discussion
During the past several years, new molecular biomarkers have
been discovered that are important targets for the diagnosis
and therapy of breast cancer [3,42]. ER and HER2/neu are
important prognostic biomarkers and therapeutic targets in
primary breast cancer. ER-negative tumors appear to be more
malignant [4,7,8,43], resulting in a poorer prognosis than with
ER-positive tumors [5,9,44]. The present study was con-
ducted to identify differences in epigenetic events related to
ER expression by infiltrating breast cancer. To date, few stud-
Table 3
Primer sequences for MSP
Gene Methylated/unmethylated Direction Sequence
RASSF1A Methylated Forward 5'-GTGTTAACGCGTTGCGTATC-3'
Reverse 5'-AACCCCGCGAACTAAAAACGA-3'
Unmethylated Forward 5'-TTTGGTTGGAGTGTGTTAATGTG-3'
Reverse 5'-CAAACCCCACAAACTAAAAACAA-3'
CCND2 Methylated Forward 5'-TACGTGTTAGGGTCGATCG-3'
Reverse 5'-CGAAAACATAAAACCTCCACG-3'
Unmethylated Forward 5'-GTTATGTTATGTTTGTTGTATG-3'
Reverse 5'-TAAAATCCACCAACACAATCA-3'
GSTP1 Methylated Forward 5'-TTCGGGGTGTAGCGGTCGTC-3'
Reverse 5'-GCCCCAATACTAAATCACGACG-3'
Unmethylated Forward 5'-GATGTTTGGGGTGTAGTGGTTGTT-3'
Reverse 5'-CCACCCCAATACTAAATCACAACA-3'
APC Methylated Forward 5'-TATTGCGGAGTGCGGGTC-3'
Reverse 5'-TCGACGAACTCCCGACGA-3'
Unmethylated Forward 5'-GTGTTTTATTGTGGAGTGTGGGTT-3'
Reverse 5'-CCAATCACAAACTCCCAACAA-3'
TWIST Methylated Forward 5'-TTTCGGATGGGGTTGTTATCG-3'
Reverse 5'-GACGAACGCGAAACGATTTC-3'
Unmethylated Forward 5'-TTGGATGGGGTTGTTATTGT-3'
Reverse 5'-ACCTTCCTCCAACAAACACA-3'
NES1 Methylated Forward 5'-TTCGAAGTTTATGGCGTTTC-3'
Reverse 5'-TTATTTCCGCAATACGCGAC-3'
Unmethylated Forward 5'-TTGTAGAGGTGGTGTTGTTT-3'
Reverse 5'-CACACAATAAAACAAAAAACCA-3'
RARβ2 Methylated Forward 5'-GAACGCGAGCGATTCGAGT-3'
Reverse 5'-GACCAATCCAACCGAAACG-3'
Unmethylated Forward 5'-GGATTGGGATGTTGAGAATGT-3'
Reverse 5'-CAACCAATCCAACCAAAACAA-3'
CDH1 Methylated Forward 5'-TTAGGTTAGAGGGTTATCGCGT-3'
Reverse 5'-TAACTAAAAATTCACCTACCGAC-3'
Unmethylated Forward 5'-TAATTTTAGGTTAGAGGGTTATTGT-3'
Reverse 5'-CACAACCAATCAACAAC ACA-3'
MSP, methylation-specific PCR.Breast Cancer Research    Vol 10 No 3    Sunami et al.
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ies have rigorously assessed matched paired ER-negative and
ER-positive primary breast tumors for epigenetic differences.
We focused on the epigenetic differences between ER-posi-
tive and ER-negative breast cancers, and used tumor speci-
men pairs matched for patient age, size, nodal status, and
presence or absence of distant metastases. This sampling
enabled rigorous analysis, and the results imply that epige-
netic features of ER-positive tumors are different from those of
ER-negative tumors.
Widschwendter and coworkers [3] demonstrated that methyl-
ation of APC correlated with ER positivity. Our data are con-
sistent with this previous report. Furthermore, we
demonstrated a significant difference in methylation status of
RASSF1A, CCND2, GSTP1, TWIST, and APC between the
ER-positive and ER-negative groups. In contrast, Li and col-
leagues [45] reported that ER-positive patients exhibited a
higher frequency of TWIST methylation and a lower frequency
of CDH1 methylation than did ER-negative patients. They also
found no significant differences in the methylation frequencies
of RARβ2, CCND2, and CDH1 between ER-positive and ER-
negative groups. The reason for the dissimilarity in study find-
ings may be due to differences in methylation analysis; Li and
colleagues assessed methylated PCR products by gel electro-
phoresis, which is more subjective and less sensitive than cap-
illary array electrophoresis analysis of methylated PCR
products. The discrepancy may also have resulted from differ-
ences in the approach to the particular specimens assessed.
Because methylation and ER status change with tumor pro-
gression [25], care should be taken when sampling ER-posi-
tive and ER-negative tumors to evaluate epigenetic changes
and clinical associations.
To clarify when differences in methylation status between ER-
positive and -negative tumors occur, we compared differences
in methylation status between T1c and T2 stage subgroups.
The ER-positive group exhibited significantly more frequent
hypermethylation of two genes (RASSF1A  and  CCND2),
independent of T stage. Moreover, the ratio of methylation fre-
quency does not differ between T1c and T2/T3 stage sub-
groups. This observation indicates that the differences in
methylation patterns do not significantly change when breast
tumors progress from T1c to T2/T3 stage. Similarly, no differ-
ence in the methylation frequency ratio was detected between
Table 4
Comparison of primary tumor gene methylation status relative 
to ER status
Gene ER negative (n = 65) ER positive (n = 65) P valuea
n % n %
RASSF1A 36 55% 60 92% <0.0001
CCND2 26 40% 45 69% 0.0008
GSTP1 4 6% 19 29% 0.0006
TWIST 17 26% 32 49% 0.0066
APC 20 31% 31 48% 0.048
NES1 13 20% 22 34% NS
RARβ2 18 28% 17 26% NS
CDH1 53 82% 54 83% NS
aχ2 test or Fisher's exact test was used appropriately. ER, estrogen 
receptor; NS, not significant.
Table 6
Comparison of primary tumor gene methylation status relative 
to T stage
Gene T1 (n = 48) T2/T3 (n = 82) P valuea
n % n %
RASSF1A 34 71% 62 77% NS
CCND2 30 63% 41 50% NS
GSTP1 9 19% 14 17% NS
TWIST 18 38% 31 38% NS
APC 17 35% 34 41% NS
aχ2 test. NS, not significant.
Table 5
Comparison of primary tumor gene methylation status relative to patient menopausal status
Gene Premenopause (n = 70) Postmenopause (n = 60) P valuea
n % n %
RASSF1A 52 74% 44 73% NS
CCND2 40 57% 31 52% NS
GSTP1 13 19% 10 17% NS
TWIST 25 36% 24 40% NS
APC 27 39% 24 40% NS
aχ2 test. NS, not significant.Available online http://breast-cancer-research.com/content/10/3/R46
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LN metastasis negative and positive tumors. Previously, we
reported that GSTP1  hypermethylation correlates with LN
metastasis [24]. Similarly in this study, only GSTP1 hyper-
methylation was found to be more frequent in the LN metasta-
sis positive group than in the negative group. In both LN
metastasis positive and negative groups, GSTP1 hypermeth-
ylation was found to be more common in ER-positive than in
ER-negative tumors. Furthermore, the differences in methyla-
tion status of RASSF1A and CCND2 between the ER-posi-
tive and ER-negative groups can be recognized in early stages
of cancer, such as the T1c or N0 stages. These findings sug-
gest that ER expression may influence epigenetic changes in
early stages of breast cancer.
HER2/neu is another important prognostic marker for breast
cancer. HER2/neu gene over-expression is identified in 15%
to 25% of invasive breast carcinomas, and is related to meta-
static potential and poor survival [35,46]. In our study, HER2/
neu over-expression was identified in 27% of breast cancers,
and was independent of ER status. A negative relation
between ER status and HER2/neu over-expression has been
documented by others [9,38,39]. One of the plausible expla-
nations for the lack of difference found in the frequency of
HER2/neu-positive tumors between the ER-negative and ER-
positive groups is that patients included in the present study
were relatively young (average age 51 years). According to
Huang and coworkers [38], in women younger than 45 years
the inverse association between ER and HER2/neu was not
apparent. Of our sample population, 37% of patients were
under 45 years old, and this age distribution may explain why
we could not detect an inverse relation between ER and
HER2/neu status. Regarding gene methylation and HER2/neu
status, Fiegl and colleagues [47] reported that methylation of
CDH13, MYOD1, PGR, and HSD17B4 exhibited a positive
association with HER2/neu expression. We demonstrated
that APC, GSTP1, and RASSF1A are more frequently methyl-
ated in the HER2/neu over-expressed group. These findings
indicate that there are epigenetic differences between HER2/
neu breast tumors, and logistic regression analysis showed
that these differences are independent of ER status.
Table 7
Comparison of primary tumor gene methylation status relative 
to nodal status
Gene N0 (n = 76) N1/N2 (n = 54) P valuea
n % n %
RASSF1A 54 71% 42 78% NS
CCND2 42 55% 29 54% NS
GSTP1 8 11% 15 28% 0.011
TWIST 28 37% 21 39% NS
APC 30 39% 21 39% NS
aχ2 test. NS, not significant.
Figure 1
Methylated and unmethylated markers Methylated and unmethylated markers. Presented are representative methylation-specific PCR results of biomarker RASSF1A from a paraffin-
embedded archival breast tissue specimens, showing methylated and unmethylated markers. bp, base pairs.Breast Cancer Research    Vol 10 No 3    Sunami et al.
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Clinically, HER2/neu-negative, ER-negative, and PR-negative
breast cancers are referred to as triple-negative breast can-
cers. About 85% of triple-negative breast tumors phenotypes
are deemed to be basal-like subtypes, and they are associated
with poor clinical outcome [48]. Because the progesterone
receptor status of our samples was not well defined, we com-
pared the methylation status of ER-negative and HER2/neu-
negative breast tumors (double-negative) with breast cancers
expressing either ER or HER2/neu. Double-negative breast
tumors exhibited frequent hypermethylation in APC, GSTP1,
RASSF1A, and TWIST, revealing the presence of epigenetic
differences between double-negative breast tumors and
breast cancers expressing either HER2/neu or ER. Further-
more, both ER and HER2/neu status contributed independ-
ently to the difference in expression of APC, GSTP1, and
RASSF1A. There is evidence that gene expression heteroge-
neity occurs in basal-like tumors of triple negatives; these sub-
groups are present with different pathology and clinical
properties. Triple negative and ER and HER2/neu-positive sta-
tus and gene expression levels of tumors may be quite hetero-
geneous in tumor populations, thus contributing to different
subclassifications. Other additional biomarkers may be
needed to subclassify phenotypes better [49,50].
Another interesting finding is the correlation of methylation sta-
tus between the tumor-related genes. Methylation status of
RASSF1A, CCND2, GSTP1, TWIST, and APC, which was
significantly higher in the ER-positive group, was correlated
with the methylation status of two or more of the four other
genes. Nonrandom distribution of methylation in tumor-related
genes has previously been reported; Nass and coworkers [51]
and Li and colleagues [45] found coincident methylation of
CDH1 and ESR1, and Parrella and coworkers [52] reported
that ESR1 promoter hypermethylation status correlates with
those of CDH1, GSTP1, CCND2, and TRb1. Our findings
revealed that occurrence of promoter region hypermethylation
of RASSF1A, CCND2, GSPT1, TWIST, and APC are associ-
ated, whereas CDH1 methylation exhibited no correlation with
methylation of those five genes (data not shown). This appar-
ent nonrandom distribution of promoter hypermethylation of
some genes suggests the existence of specific factors caus-
ing selective promoter region hypermethylation of tumor-
related genes.
Conclusion
In this study, we demonstrated – for the first time – that epige-
netic differences between ER-positive and ER-negative breast
tumors arise early in cancer development and persist during
cancer progression. Furthermore, we reported epigenetic dif-
ferences between HER2/neu-positive and HER2/neu-nega-
tive breast tumors, and between double-negative breast
tumors and breast tumors expressing either HER2/neu or ER.
Table 8
Methylated primary ER-negative and ER-positive tumors: T1c and T2/T3 subgroups
T1c (n = 48) T2/T3 (n = 82)
Gene ER negative (n = 24) ER positive (n = 24) P valuea ER negative (n = 41) ER positive (n = 41) P valuea
RASSF1A 13 (54%) 21 (88%) 0.011 23 (56%) 39 (95%) <0.0001
CCND2 10 (42%) 20 (83%) 0.0029 16 (39%) 25 (61%) 0.0468
GSTP1 3 (13%) 6 (25%) NS 1 (2%) 13 (32%) 0.0004
TWIST 6 (25%) 12 (50%) NS 11 (27%) 20 (49%) 0.0404
APC 9 (38%) 8 (33%) NS 11 (27%) 23 (56%) 0.0071
aχ2 test or Fisher's exact test was used appropriately. ER, estrogen receptor; NS, not significant.
Table 9
Methylated primary ER-negative and ER-positive tumors: N0 and N1/N2 subgroups
N0 (n = 76) N1/N2 (n = 54)
Genes ER negative (n = 38) ER positive (n = 38) P valuea ER negative (n = 27) ER positive (n = 27) P valuea
RASSF1A 18 (47%) 36 (95%) <0.0001 18 (67%) 24 (89%) 0.0495
CCND2 16 (42%) 26 (68%) 0.021 10 (37%) 19 (70%) 0.014
GSTP1 1 (3%) 7 (18%) 0.025 3 (11%) 12 (44%) 0.0062
TWIST 11 (29%) 17 (45%) NS 6 (22%) 15 (56%) 0.012
APC 11 (29%) 19 (50%) NS 9 (33%) 12 (44%) NS
aχ2 test or Fisher's exact test was used appropriately. ER, estrogen receptor; NS, not significant.Available online http://breast-cancer-research.com/content/10/3/R46
Page 9 of 11
(page number not for citation purposes)
Taking advantage of potential reversibility of DNA methylation,
epigenetic therapies directed against various cancers have
been in development; 5-azacytidine, 5-aza-2'-deoxycytidines,
procainamide, and hydralazine are promising agents. Investi-
gators are attempting to combine epigenetic therapy with
other standard therapies [2,53]. For breast cancer, one
approach may to combine hormone therapy and antimethyla-
tion treatment. Integrated information regarding clinical factors
influencing therapeutic principles and epigenetic features,
such as promoter hypermethylation of tumor-related genes,
will be important for combining epigenetics targeting drugs
and standard chemotherapy.
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Table 10
Comparison of primary tumor gene methylation status relative to HER2/neu status
HER2/neu negative (n = 78) HER2/neu positive (n = 29) P valuea
Gene n % n %
RASSF1A 55 71% 27 93% 0.007
CCND2 44 56% 15 52% NS
GSTP1 10 13% 12 41% 0.0019
TWIST 29 37% 11 38% NS
APC 26 33% 17 59% 0.0185
NES1 22 28% 7 24% NS
RARβ2 20 26% 11 38% NS
CDH1 68 87% 20 67% 0.036
aχ2 test or Fisher's exact test was used appropriately. HER, human epidermal growth factor receptor; NS, not significant.
Table 11
Comparison of primary tumor gene methylation status relative to double-negative breast cancers versus cancers expressing either 
ER or HER2/neu
Gene Double negative (n = 37) Either ER positive or HER2/neu positive (n = 70) P valuea
n % n %
RASSF1A 18 47% 64 91% <0.0001
CCND2 16 43% 43 61% NS
GSTP1 0 0% 22 31% <0.0001
TWIST 7 19% 33 47% 0.0031
APC 8 22% 35 50% 0.0035
NES1 8 22% 21 30% NS
RARβ2 10 27% 21 30% NS
CDH1 33 89% 55 79% NS
aχ2 test or Fisher's exact test was used appropriately. ER, estrogen receptor; NS, not significant; HER, human epidermal growth factor.Breast Cancer Research    Vol 10 No 3    Sunami et al.
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